^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Yutuo (zimberelimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1163 Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
Published date:
11/04/2020
Excerpt:
...For all the 85 pts, ORR was 90.59% (77/85, 95%CI: 82.30-95.85) with 32.9% (28/85) of patients achieving a CR and 57.6% (49/85) of patients achieving a PR (Table 3). Median duration of response (DoR) and progression free survival (PFS) were not reached yet.GLS-010 showed impressive anti-tumor activity (ORR=90.59%) and manageable safety profile in Chinese patients with relapsed or refractory cHL, and could be a new safe and effective treatment option.
